Aldosterone News and Research RSS Feed - Aldosterone News and Research

Aldosterone is a steroid hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps control the balance of water and salts in the kidney by keeping sodium in and releasing potassium from the body. Too much aldosterone can cause high blood pressure and a build-up of fluid in body tissues. Aldosterone is a type of mineralocorticoid hormone.
Ancient Chinese practice lowers hypertension, may lessen risks of stroke and heart disease

Ancient Chinese practice lowers hypertension, may lessen risks of stroke and heart disease

Patients with hypertension treated with acupuncture experienced drops in their blood pressure that lasted up to a month and a half, researchers with the Susan Samueli Center for Integrative Medicine have found. [More]
ESC Congress to highlight results from global trials in six press conferences

ESC Congress to highlight results from global trials in six press conferences

Members of the press will be the first to hear the highly anticipated results from global trials in six press conferences devoted to hot lines research. [More]
New research could help develop precision medicine for primary aldosteronism

New research could help develop precision medicine for primary aldosteronism

Each of your kidneys wears a little yellow cap that helps keep your blood pressure in check, and much more. But in some people, it starts running amok, pumping out a hormone that sends blood pressure sky-high. [More]
Scientists decipher new molecular signaling path that prompts protein degradation in muscle

Scientists decipher new molecular signaling path that prompts protein degradation in muscle

Patients in advanced states of myocardial insufficiency generally lose their muscle mass and muscle strength. Indeed a fact that until now has negatively impacted the clinical course of the disease and that has resulted in poor prognoses for patients. Such pathological muscle loss impacts the skeletal muscles in particular. [More]
Six hot line sessions set to reveal latest research in cardiovascular disease at ESC Congress 2015

Six hot line sessions set to reveal latest research in cardiovascular disease at ESC Congress 2015

Six hot line sessions at ESC Congress 2015 are set to reveal the latest in cardiovascular disease research across a range of conditions and comorbidities. Hot topics include atrial fibrillation, pacing, acute myocardial infarction, heart failure, hypertension, diabetes mellitus, pharmacology and coronary artery disease. [More]
New drug patiromer could improve potassium levels of patients with diabetic kidney disease

New drug patiromer could improve potassium levels of patients with diabetic kidney disease

Among patients with diabetic kidney disease and hyperkalemia (elevated potassium levels in the blood), a potentially life-threatening condition, those who received the new drug patiromer, twice daily for four weeks, had significant decreases in potassium levels which lasted through one year, according to a study in the July 14 issue of JAMA. [More]
Hormones used in breast cancer treatment could affect disease progression, outcomes in some patients

Hormones used in breast cancer treatment could affect disease progression, outcomes in some patients

Recently, researchers have discovered that the hormone progesterone, an ingredient in contraceptives and menopausal hormone replacement therapies, might stimulate the growth of breast cancer cells that are resistant to anti-estrogen therapy and chemotherapy. [More]
Aldosterone/renin ratio reliable diagnostic tool in infant primary hypoaldosteronism

Aldosterone/renin ratio reliable diagnostic tool in infant primary hypoaldosteronism

The ratio of aldosterone to renin in plasma is a reliable indicator of primary hypoaldosteronism in newborns and infants, say researchers. [More]
New oral drug shows promise in patients with chronic kidney disease

New oral drug shows promise in patients with chronic kidney disease

Patients with chronic kidney disease may be treated with a class of medications called Renin Angiotensin Aldosterone System inhibitors (RAASI's). Although these drugs protect the heart and kidney, a significant percentage of patients develop a dangerous side effect -- high potassium levels in the blood (hyperkalemia). [More]
Spironolactone drug reduces side effects of corticosteroid-based dermatological creams

Spironolactone drug reduces side effects of corticosteroid-based dermatological creams

Basic research on blood pressure has led researchers from Inserm (Inserm Unit 1138, "Cordeliers Research Centre") to obtain unexpected results: drugs used to treat hypertension (high blood pressure) reduce side effects from corticosteroid-based creams used to treat certain skin diseases. [More]
Chronic heart failure patients with decreased calcitriol may benefit from aggressive supplementation

Chronic heart failure patients with decreased calcitriol may benefit from aggressive supplementation

In patients with chronic heart failure, the vitamin D metabolite 1,25-dihydroxyvitamin D (1,25(OH)2D), also called calcitriol, and its ratio to parathyroid hormone (PTH 1-84) may help predict cardiovascular death; and patients with decreased calcitriol and decreased ratio of calcitriol to PTH might benefit from more aggressive supplementation, a new study finds. [More]
Novartis’ heart failure medicine LCZ696 granted FDA priority review

Novartis’ heart failure medicine LCZ696 granted FDA priority review

LCZ696, a twice-a-day medicine being investigated for heart failure, acts to enhance the protective neurohormonal systems of the heart (NP system) while simultaneously suppressing the harmful effects of the overactive renin-angiotensin-aldosterone system (RAAS). [More]
Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis announced today that the US Food and Drug Administration has granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation is intended to accelerate the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition. [More]
Not all ARB drugs are equally effective at treating heart failure, reveals NSU researcher

Not all ARB drugs are equally effective at treating heart failure, reveals NSU researcher

Millions of people take angiotensin receptor blockers (ARBs) to help treat heart failure. But it turns out not all ARBs are created equally, according to one Nova Southeastern University researcher's findings. [More]
Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Research published today found that the investigational drug patiromer decreased high potassium levels and maintained normal potassium levels in patients with chronic kidney disease. The results of a multicenter trial appear in the New England Journal of Medicine. [More]
Taking NSAIDs with other drugs can increase risk of upper GI bleeding, study finds

Taking NSAIDs with other drugs can increase risk of upper GI bleeding, study finds

Nonsteroidal anti-inflammatory drugs (NSAIDs) - such as ibuprofen and aspirin - increase one's risk of upper gastrointestinal bleeding. When taken in combination with other drugs, this risk is significantly higher, according to new research appearing in the October issue of Gastroenterology, the official journal of the American Gastroenterological Association. [More]
Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas. [More]
Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet. [More]
PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

The PARADIGM-HF trial has been stopped early for a benefit to patients that was overwhelmingly statistically significant. [More]
ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that it has begun enrolling patients in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia. [More]
Advertisement
Advertisement